Francesca Finotello

Francesca Finotello

Auto-generated profile, based on publicly available information

Francesca Finotello

Department of Molecular Biology, Digital Science Center (DiSC), University of Innsbruck, 6020 Innsbruck, Tyrol, Austria

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in Cell Reports
Verified
Journal Article
Open access
PCPornpimol Charoentong
Pornpimol Charoentong
FFFrancesca Finotello
Francesca Finotello
MAMihaela Angelova
Mihaela Angelova
CMClemens Mayer
Clemens Mayer
MEMirjana Efremova
Mirjana Efremova
ZTZlatko Trajanoski
Zlatko Trajanoski
The Cancer Genome Atlas revealed the genomic landscapes of human cancers. In parallel, immunotherapy is transforming the treatment of advanced cancers. Unfortunately, the majority of patients do not respond to immunotherapy, making the identification of predictive markers and the mechanisms of resistance an area of intense research. To increase our understanding of tumor-immune cell interactions, we characterized the intratumoral immune landscapes and the cancer antigenomes from 20 solid cancers and created The Cancer Immunome Atlas (https://tcia.at/). Cellular characterization of the immune infiltrates showed that tumor genotypes determine immunophenotypes and tumor escape mechanisms. Using machine learning, we identified determinants of tumor immunogenicity and developed a scoring scheme for the quantification termed immunophenoscore. The immunophenoscore was a superior predictor of response to anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) and anti-programmed cell death protein 1 (anti-PD-1) antibodies in two independent validation cohorts. Our findings and this resource may help inform cancer immunotherapy and facilitate the development of precision immuno-oncology.

24 May 2019 in Genome Medicine
Verified
Journal Article
Open access
PDF file
FFFrancesca Finotello
Francesca Finotello
CMClemens Mayer
Clemens Mayer
CPChristina Plattner
Christina Plattner
GLGerhard Laschober
Gerhard Laschober
DRDietmar Rieder
Dietmar Rieder
ZTZlatko Trajanoski
Zlatko Trajanoski
We introduce quanTIseq, a method to quantify the fractions of ten immune cell types from bulk RNA-sequencing data. quanTIseq was extensively validated in blood and tumor samples using simulated, flow cytometry, and immunohistochemistry data. quanTIseq analysis of 8000 tumor samples revealed that cytotoxic T cell infiltration is more strongly associated with the activation of the CXCR3/CXCL9 axis than with mutational load and that deconvolution-based cell scores have prognostic value in several solid cancers. Finally, we used quanTIseq to show how kinase inhibitors modulate the immune contexture and to reveal immune-cell types that underlie differential patients’ responses to checkpoint blockers. Availability: quanTIseq is available at http://icbi.at/quantiseq.

5 July 2019 in Bioinformatics
Verified
Journal Article
Open access
PDF file
GSGregor Sturm
Gregor Sturm
FFFrancesca Finotello
Francesca Finotello
FPFlorent Petitprez
Florent Petitprez
JZJitao David Zhang
Jitao David Zhang
Jan BaumbachJan Baumbach
Jan Baumbach
TATatsiana Aneichyk
Tatsiana Aneichyk
The composition and density of immune cells in the tumor microenvironment (TME) profoundly influence tumor progression and success of anti-cancer therapies. Flow cytometry, immunohistochemistry staining or single-cell sequencing are often unavailable such that we rely on computational methods to estimate the immune-cell composition from bulk RNA-sequencing (RNA-seq) data. Various methods have been proposed recently, yet their capabilities and limitations have not been evaluated systematically. A general guideline leading the research community through cell type deconvolution is missing. We developed a systematic approach for benchmarking such computational methods and assessed the accuracy of tools at estimating nine different immune- and stromal cells from bulk RNA-seq samples. We used a single-cell RNA-seq dataset of ∼11 000 cells from the TME to simulate bulk samples of known cell type proportions, and validated the results using independent, publicly available gold-standard estimates. This allowed us to analyze and condense the results of more than a hundred thousand predictions to provide an exhaustive evaluation across seven computational methods over nine cell types and ∼1800 samples from five simulated and real-world datasets. We demonstrate that computational deconvolution performs at high accuracy for well-defined cell-type signatures and propose how fuzzy cell-type signatures can be improved. We suggest that future efforts should be dedicated to refining cell population definitions and finding reliable signatures. A snakemake pipeline to reproduce the benchmark is available at https://github.com/grst/immune_deconvolution_benchmark. An R package allows the community to perform integrated deconvolution using different methods (https://grst.github.io/immunedeconv). Supplementary data are available at Bioinformatics online.

8 September 2014 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
JFJoão Fadista
João Fadista
PVPetter Vikman
Petter Vikman
ELEmilia Ottosson Laakso
Emilia Ottosson Laakso
IMInês Mollet
Inês Mollet
Jonathan EsguerraJonathan Esguerra
Jonathan Esguerra
LGLeif Groop
Leif Groop
Significance: We provide a comprehensive catalog of novel genetic variants influencing gene expression and metabolic phenotypes in human pancreatic islets. The data also show that the path from genetic variation (SNP) to gene expression is more complex than hitherto often assumed, and that we need to consider that genetic variation can also influence function of a gene by influencing exon usage or splice isoforms (sQTL), allelic imbalance, RNA editing, and expression of noncoding RNAs, which in turn can influence expression of target genes.

10 April 2023 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
IVIsaac Virshup
Isaac Virshup
DBDanila Bredikhin
Danila Bredikhin
LHLukas Heumos
Lukas Heumos
GPGiovanni Palla
Giovanni Palla
GSGregor Sturm
Gregor Sturm
FTFabian J. Theis
Fabian J. Theis

14 March 2018 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Open access
PDF file
FFFrancesca Finotello
Francesca Finotello
ZTZlatko Trajanoski
Zlatko Trajanoski
By exerting pro- and anti-tumorigenic actions, tumor-infiltrating immune cells can profoundly influence tumor progression, as well as the success of anti-cancer therapies. Therefore, the quantification of tumor-infiltrating immune cells holds the promise to unveil the multi-faceted role of the immune system in human cancers and its involvement in tumor escape mechanisms and response to therapy. Tumor-infiltrating immune cells can be quantified from RNA sequencing data of human tumors using bioinformatics approaches. In this review, we describe state-of-the-art computational methods for the quantification of immune cells from transcriptomics data and discuss the open challenges that must be addressed to accurately quantify immune infiltrates from RNA sequencing data of human bulk tumors.